Skip to content

A clinical study on Unani formulation in Insomnia.

A Clinical Evaluation on Insomnia (Sahr) and Its Management with a Polyherbal Unani Formulation: An Open-Label, Single-Arm Study. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105692
Enrollment
30
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F510- Insomnia not due to a substance orknown physiological condition

Interventions

Intervention1: Polyherbal Unani Formulation: 9gm at night for 28 days Intervention2: Polyherbal Unani Formulation (Powder): 9gm at night for 28 days Control Intervention1: NIL: NIL

Sponsors

Ayurvedic and Unani Tibbia College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosed with primary insomnia as per ICSD-3 criteria. 2.Willing to give written informed consent and comply with study procedures. 3.Willing to discontinue other medications or therapies for insomnia during the trial.

Exclusion criteria

Exclusion criteria: 1.History of major medical illness: uncontrolled hypertension, diabetes mellitus, hepatic or renal dysfunction, respiratory (COPD), cardiovascular or neurological diseases. 2.Use of sedatives, antidepressants, hypnotics, or other CNS-affecting medications within the last 2 weeks. 3.Pregnant or lactating women. 4.Known allergy or hypersensitivity to any component of the Unani formulation. 5.Presence of other sleep disorders, such as: Obstructive Sleep Apnea (OSA), Restless Legs Syndrome, Narcolepsy, Circadian rhythm disorder. 6.Current or recent history (past 6 months) of alcoholism or drug dependence

Design outcomes

Primary

MeasureTime frame
To assess the safety and efficacy of the proposed Unani Polyherbal Formulation in the management of Insomnia on scientific parameters.Timepoint: 1.To evaluate efficacy: Assessment of Insomnia Severity Index on baseline and 28th day. 2.To evaluate safety: Haemogram , LFT, KFT at baseline and 28th day.

Secondary

MeasureTime frame
To evaluate the effects of Unani Polyherbal Formulation on the Quality of life of the patient of Insomnia.Timepoint: Assessment of Quality of life Index at baseline and after 28th day.

Countries

India

Contacts

Public ContactMisbah Shafaq

Ayurvedic and Unani Tibbia College and Hospital

drkhannaseem.akhtarkhan@gmail.com9810815997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026